These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 7574507)

  • 41. Identification of the benzodiazepines as a new class of antileishmanial agent.
    Clark RL; Carter KC; Mullen AB; Coxon GD; Owusu-Dapaah G; McFarlane E; Duong Thi MD; Grant MH; Tettey JN; Mackay SP
    Bioorg Med Chem Lett; 2007 Feb; 17(3):624-7. PubMed ID: 17113290
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lower nitric oxide susceptibility of trivalent antimony-resistant amastigotes of Leishmania infantum.
    Holzmuller P; Sereno D; Lemesre JL
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4406-9. PubMed ID: 16189135
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis.
    Perry MR; Wyllie S; Raab A; Feldmann J; Fairlamb AH
    Proc Natl Acad Sci U S A; 2013 Dec; 110(49):19932-7. PubMed ID: 24167266
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Snapshot Profiling of the Antileishmanial Potency of Lead Compounds and Drug Candidates against Intracellular Leishmania donovani Amastigotes, with a Focus on Human-Derived Host Cells.
    Koniordou M; Patterson S; Wyllie S; Seifert K
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069646
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Experimental studies on the evolution of antimony-resistant phenotype during the in vitro life cycle of Leishmania infantum: implications for the spread of chemoresistance in endemic areas.
    Sereno D; Guilvard E; Maquaire S; Cavaleyra M; Holzmuller P; Ouaissi A; Lemesre JL
    Acta Trop; 2001 Dec; 80(3):195-205. PubMed ID: 11700176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility.
    Barrera MC; Rojas LJ; Weiss A; Fernandez O; McMahon-Pratt D; Saravia NG; Gomez MA
    Acta Trop; 2017 Dec; 176():355-363. PubMed ID: 28843396
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of
    Özbilgin A; Çavuş İ; Kaya T; Yıldırım A; Harman M
    Turkiye Parazitol Derg; 2020 Mar; 44(1):12-16. PubMed ID: 32212583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glucantime resistant Leishmania promastigotes are sensitive to pentostam.
    Moreira ES; Guerra JB; Petrillo-Peixoto Mde L
    Rev Soc Bras Med Trop; 1992; 25(4):247-50. PubMed ID: 1340539
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improved antileishmanial activity of Dppz through complexation with antimony(III) and bismuth(III): investigation of the role of the metal.
    Lizarazo-Jaimes EH; Monte-Neto RL; Reis PG; Fernandes NG; Speziali NL; Melo MN; Frézard F; Demicheli C
    Molecules; 2012 Oct; 17(11):12622-35. PubMed ID: 23099618
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Leishmania spp.: development of pentostam-resistant clones in vitro by discontinuous drug exposure.
    Grögl M; Oduola AM; Cordero LD; Kyle DE
    Exp Parasitol; 1989 Jul; 69(1):78-90. PubMed ID: 2543590
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro efficacy of some drugs on promastigotes of Leishmania donovani.
    Al-Khateeb GH; Al-Jeboori TI; Al-Janabi KA
    Chemotherapy; 1977; 23(4):267-75. PubMed ID: 16732
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The synergistic action of pyrazolopyrimidines and pentavalent antimony against Leishmania donovani and L. braziliensis.
    Martinez S; Looker DL; Berens RL; Marr JJ
    Am J Trop Med Hyg; 1988 Sep; 39(3):250-5. PubMed ID: 2845824
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fine-structural alterations in Leishmania tropica within human macrophages exposed to antileishmanial drugs in vitro.
    Langreth SG; Berman JD; Riordan GP; Lee LS
    J Protozool; 1983 Aug; 30(3):555-61. PubMed ID: 6315928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Growth of Leishmania donovani amastigotes in the continuous human macrophage cell line U937: studies of drug efficacy and metabolism.
    Looker DL; Martinez S; Horton JM; Marr JJ
    J Infect Dis; 1986 Aug; 154(2):323-7. PubMed ID: 3014012
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activity of nicotinamide/antileishmanial drug combinations.
    Gazanion E; Vergnes B; Seveno M; Garcia D; Oury B; Ait-Oudhia K; Ouaissi A; Sereno D
    Parasitol Int; 2011 Jan; 60(1):19-24. PubMed ID: 20884376
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovani.
    Seifert K; Munday J; Syeda T; Croft SL
    J Antimicrob Chemother; 2011 Apr; 66(4):850-4. PubMed ID: 21393188
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis.
    Berman JD; Wyler DJ
    J Infect Dis; 1980 Jul; 142(1):83-6. PubMed ID: 6249874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites.
    Brochu C; Wang J; Roy G; Messier N; Wang XY; Saravia NG; Ouellette M
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3073-9. PubMed ID: 14506011
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Susceptibility of Leishmania to novel pentavalent organometallics: Investigating impact on DNA and membrane integrity in antimony(III)-sensitive and -resistant strains.
    Islam A; do Prado BR; Dittz D; Rodrigues BL; Silva SMD; do Monte-Neto RL; Shabeer M; Frézard F; Demicheli C
    Drug Dev Res; 2024 May; 85(3):e22194. PubMed ID: 38704828
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Leishmania donovani: effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Indian clinical isolates to sodium stibogluconate.
    Valiathan R; Dubey ML; Mahajan RC; Malla N
    Exp Parasitol; 2006 Oct; 114(2):103-8. PubMed ID: 16616137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.